Clinical trial · Observational
Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.
Clinical Investigation of the OV-Watch™ Personal Fertility Monitor for Women Undergoing Ovulation Induction With Clomiphene Citrate.
NCT00239603CI-TRIAL-00000678completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effectiveness of the OV-Watch to predict ovulation while women are taking clomiphene citrate.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anovulation | — | UNRESOLVED | — |
| Infertility | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OV-Watch | Device | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 42 Years
Show eligibility criteria text
Inclusion Criteria: * Patients eligible to participate must be between the age of 21 and 42. * Patient must demonstrate ability to follow standard clomiphene citrate ovulation induction protocol and wear the OV-Watch™ correctly. * Intact uterus and at least one ovary must be present. * Patients must be diagnosed with anovulation (lack of ovulation) that is not caused by hypothalamic amenorrhea or premature ovarian failure. * A hysterosalpingogram must be performed to demonstrate at least one patent fallopian tube. The uterine cavity must also appear normal on this study. * The male partner or sperm donor must demonstrate an acceptable concentration and motility of sperm. Exclusion Criteria: * 12 or more previous treatment cycles using clomiphene citrate. * Any condition where the use of clomiphene is contraindicated, such as breast cancer or liver disease. * Any other hormonal disease that may be secondarily causing anovulation, such as thyroid disorder or hyperprolactinemia. * Amenorrhea caused by premature ovarian failure or hypothalamic amenorrhea. * Any active genital tract infection will need to be treated with antibiotics before undergoing ovulation induction.
References
Publications (0)
Data not yet available
No reference posted for this study.